免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：info@selleck.cn

Idelalisib

目录号：S2226 别名: CAL-101, GS-1101 中文名称：艾代拉里斯，艾代拉利司

仅限科研使用

Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 还可诱导自噬。

CAS: 870281-82-6

规格	价格	库存
10mM (1mL in DMSO)	RMB 1279.19	现货
10mg	RMB 972.85	现货
50mg	RMB 3867.24	现货
200mg	RMB 10401.3	现货
大包装	有超大折扣
大剂量询单有大折扣!
今日订购，明日送达全国免运费分装免费分装成小规格产品（单支最小为1mg）如1支10mg产品可分装为10支1mg产品全国免费电话：400-668-6834 \| Email：info@selleck.cn

客户使用Selleck生产的Idelalisib 发表文献231篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

靶点

p110δ ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)
2.5 nM	89 nM

体外研究

CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达，EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比，CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞，降低pAktS473, pAktT308, 和下游靶点S6， EC50为0.1到1.0 μM。 ^[1] CAL-101 作用于CLL细胞，诱导选择性细胞毒性，不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比，CAL-101作用于CLL 细胞优先产生细胞毒性，和LY294002相比，作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。^[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累，在S期下降，说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

MEC1	M1zneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHzmelBFVVOR	M4nadmlEPTB;MkCuOEDPxE1?	MlqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7OUmzOVIoRjJ3OUm5N\|UzRC:jPh?=
CLL PBMCs	M4DKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmTGSG1UVw>?	NU\4V2N1UUN3ME2yMlkhdk1?	M4[zVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG3NlY4Lz5{NUmxO\|I3PzxxYU6=
U266	NV20PXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4WwV\|QxKM7:TR?=	MkHWOFghcA>?		NYXtUnhkPzlwNTWgbY5pcWKrdHnvckBz[XSn	MknpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{mzN\|IoRjJ3M{O5N\|MzRC:jPh?=
K562	NHKycWRHfW6ldHnvckBCe3OjeR?=	MWCxJO69VQ>?	M2TjVFMhcA>?		MoHmTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w	MlPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
K562	Mn22SpVv[3Srb36gRZN{[Xl?	MnewNUDPxE1?	NH3EUoE{KGh?		M2T0WmlvcGmkaYTpc44hd2ZiUEewV\|ZMKHCqb4PwbI9zgWyjdHnvci=>	NGn3elk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
K562	MVTGeY5kfGmxbjDBd5NigQ>?	M12zNVEh\|ryP	NYX6NIlLOyCq		M2PT[GlvcGmkaYTpc44hd2ZiR2PLN{BxcG:\|cHjvdplt[XSrb36=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzNEe3OUc,OjVyMUS3O\|U9N2F-
K562	M{HwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTJZnR5OSEQvF2=	NEW1OpE4OiCq		MmPITY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;u	M{PLWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell	M1\zdGZ2dmO2aX;uJGF{e2G7	MoO4NUDPxE1?	NF;rPYE{KGh?		NX\t[GcyUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	M3y1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell	Mo[5SpVv[3Srb36gRZN{[Xl?	NG\TTZAyKM7:TR?=	MVKzJIg>		M4\xOGlvcGmkaYTpc44hd2ZiUEewV\|ZMKHCqb4PwbI9zgWyjdHnvci=>	MnjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
Primary AML cell	MUfGeY5kfGmxbjDBd5NigQ>?	NHvPXJgyKM7:TR?=	M33zdVMhcA>?		MmPZTY5pcWKrdHnvckBw\iCJU1uzJJBpd3OyaH;yfYxifGmxbh?=	MkXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
Primary AML cell	NXnHZ\|h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PZblEh\|ryP	MlLvN{Bp		M36yXXN2eHC{ZYPzbY9vKG:oIILSUmEhe3mwdHjld4l{	MnfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O\|UoRjJ3MEG0O\|c2RC:jPh?=
Microglia	NWPtdXlMTnWwY4Tpc44hSXO\|YYm=	M1:0WVUh\|ryP	NULBcWNPOTBiaB?=	MX\EUXNQ	M4nDTGRm[3KnYYPlJI9nKFSQRnGgd4VkemW2aX;uJIZzd21iTGDTMZN1cW23bHH0[YQhKHBzMUFOuGQ6OTCDL1S5NVBCKG2rY4Lv[4xq[Q>?	NYD6dFd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlU3QDRpPkK0OlI2Pjh2PD;hQi=>
Primary CLL cell	M4LvOGZ2dmO2aX;uJGF{e2G7	MlPNNUDPxE1?	MmHHNVUhdWmw	NXftbJVDTE2VTx?=	NIrse2ZDdG:la4OgRmNTNWmwZIXj[YQhVEOSMTDz[ZJqdmVvNTDhZ5RqfmG2aX;u	Ml7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMEmyN\|MoRjJ2MEC5NlM{RC:jPh?=
JEKO-1	MW\GeY5kfGmxbjDBd5NigQ>?	NHyzXVEyKM7:TR?=	MYG3NkBp		MkO1TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJGloVS2\|dHnteYxifGWmIFrFT28uOQ>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2MUW0NUc,OjN\|NEG1OFE9N2F-
Granta-519	NGjyXJNHfW6ldHnvckBCe3OjeR?=	MXyxJO69VQ>?	NEjWeXYzKGh?		NHfPWJhKdmirYnn0bY9vKG:oIFHreEh1OzB6KTDwbI9{eGixconsZZRqd25?	NXzNOWVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFE2PDFpPkKzN\|QyPTRzPD;hQi=>
Granta-519	NXnhUpE5TnWwY4Tpc44hSXO\|YYm=	MmDhNUDPxE1?	NX\WdHZwOiCq		M1nNUGlvcGmkaYTpc44hd2ZiQXv0LJM1PzNrIIDoc5NxcG:{eXzheIlwdg>?	M4Ljc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{SxOVQyLz5{M{O0NVU1OTxxYU6=
JEKO-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWT4TpNCOTBizszN	MWi3NkBp		M3fGemlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckB{dGmpaITsfS=>	NVPHVmRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOFE2PDFpPkKzN\|QyPTRzPD;hQi=>
JEKO-1	NULwdGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HOTlUh\|ryP	NVSwRnhmPzJiaB?=		NFrFfoZld2W\|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{	NVXnRW06RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|YzOjBpPkKzOlc3OjJyPD;hQi=>
MAVER-1	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPQOUDPxE1?	Mlq2O\|IhcA>?		NWfwOY1u\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>?	Mn\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4N{[yNlAoRjJ\|Nke2NlIxRC:jPh?=
MINO	NVm5RXlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXPN\|U2KM7:TR?=	NGK0UZE4OiCq		NFTx[3pld2W\|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F-
SP53	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPr[JR2OC5zIN88US=>	NHni[XU4OiCq		M1jqT4Rw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW\|dDDvdkBieG:ydH;zbZM>	M4P4UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nke2NlIxLz5{M{[3OlIzODxxYU6=
HH	NWjGOGxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFX5Om8yOCEQvF2=	MYC3NkBp	MkHkSG1UVw>?	MmLNTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyC\|bHnnbJRtgQ>?	NH7weoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+
Myla	M3nM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVOxNEDPxE1?	NG\OfGY4OiCq	MYfEUXNQ	M3uydYRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYO=	NWDwNokzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFE6PTlpPkKyPFAyQTV7PD;hQi=>
SR786	NEjERoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPoNVAh\|ryP	NF3KSHM4OiCq	NU\lcphJTE2VTx?=	MoL5[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
HuT78	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnm1NVAh\|ryP	NFqxO3M4OiCq	Mlf1SG1UVw>?	M2nxUIRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYO=	M1HoW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6=
MJ	NITPRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWqxNEDPxE1?	NXHLWolZPzJiaB?=	NVjtRYNmTE2VTx?=	NWH5PVBZ\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=>	Ml;hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
DERL7	Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\1dnMyOCEQvF2=	M1La[\|czKGh?	NVXl[mhHTE2VTx?=	MYTkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|	M17BWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6=
L1236	NXLTS4FjTnWwY4Tpc44hSXO\|YYm=	NEH5UVUyOCEQvF2=	NH7rRYIzKGh?		MlzKTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L428	MWTGeY5kfGmxbjDBd5NigQ>?	MmntNVAh\|ryP	NV\pZYM3OiCq		NILQTm9KdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36=	NVT6VFM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L591	M2C2SGZ2dmO2aX;uJGF{e2G7	NUXRUItOOTBizszN	NUi4bG9YOiCq		M1HUU2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?=	M4q2VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGwPFc4Lz5{MkKxNFg4PzxxYU6=
KMH-2	MUPGeY5kfGmxbjDBd5NigQ>?	M2jIV\|ExKM7:TR?=	MV6yJIg>		MoS5TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L1236	M4jRVmZ2dmO2aX;uJGF{e2G7	NXL6OI1xPSEQvF2=	M1vzflI1KGh?		MlzXRoxw[2u\|IIPlZ5JmfGmxbjDv[kB1cGViQ1PMOS=>	NFrQTJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
L591	NFnyUG9HfW6ldHnvckBCe3OjeR?=	MUW1JO69VQ>?	NFzFRo8zPCCq		Mnf0Roxw[2u\|IIPlZ5JmfGmxbjDv[kB1cGViQ1PMOS=>	NWj0UoVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L1236	MYHBdI9xfG:\|aYOgRZN{[Xl?	MYG1JO69VQ>?	MU[yOEBp		MYLJcoR2[3Srb36gc4Yh[XCxcITvd4l{	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L591	NELiRoNCeG:ydH;zbZMhSXO\|YYm=	M1mwN\|Uh\|ryP	MX:yOEBp		NHPVcXVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	NEPRW4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
U-87MG	M2HmXWZ2dmO2aX;uJGF{e2G7	NIjQdHoyODBibl2=	NF;mV4gzPCCq	MXjEUXNQ	MVrJcohq[mm2aX;uJI9nKCClZXzsJI1q\3KjdHnvci=>	NXraVGVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO\|k3ODlpPkKyNFc6PjB7PD;hQi=>
SW1783	NHrEdlhHfW6ldHnvckBCe3OjeR?=	NWLQUHpTOTByIH7N	MYqyOEBp	NV;GenNETE2VTx?=	M3j2OGlvcGmkaYTpc44hd2ZiIHPlcIwhdWmpcnH0bY9v	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F-
U-87MG	NHH2TJJHfW6ldHnvckBCe3OjeR?=	NEnNW2M2KM7:TR?=	NHXYTI0zPCCq	M{C3dGROW09?	NIK2WoVKdmirYnn0bY9vKG:oIFHreEBxcG:\|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>?	NV7QNWFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO\|k3ODlpPkKyNFc6PjB7PD;hQi=>
SW1783	NFnSb3FHfW6ldHnvckBCe3OjeR?=	M2jIS\|Uh\|ryP	MWeyOEBp	NVLzbHg{TE2VTx?=	MXvJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=>	NGjYZ4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO\|k3ODl:L3G+
U-373MG	NHfG[ZBHfW6ldHnvckBCe3OjeR?=	MWK1JO69VQ>?	MljpNlQhcA>?	MXTEUXNQ	M{frRWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6	MnPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{m2NFkoRjJ{MEe5OlA6RC:jPh?=
SK-MG3	M3zsXWZ2dmO2aX;uJGF{e2G7	NUXPVGk2PSEQvF2=	NWPuXmxbOjRiaB?=	MUTEUXNQ	NXLwcZQyUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl?	NHfrR4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO\|k3ODl:L3G+
SU-DHL-5	M1nLSmZ2dmO2aX;uJGF{e2G7	NWXCOo9yOSEQvF2=	Mo\iNlQhcA>?	NIroNJlFVVOR	NVPiVoxwUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	M4nqS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOUW5OlA3Lz5{MEm1PVYxPjxxYU6=
WSU-NHL	M2LrN2Z2dmO2aX;uJGF{e2G7	Mle5NUDPxE1?	NUPablFOOjRiaB?=	NYW0SJZnTE2VTx?=	NWTxPJRoUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	MnL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7NUm2NFYoRjJyOUW5OlA3RC:jPh?=
CCRF-SB	MV;GeY5kfGmxbjDBd5NigQ>?	NHftZ3AyKM7:TR?=	NXnPbYJlOjRiaB?=	MVTEUXNQ	NVeyUlJGUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	NX20Tms2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OVk3ODZpPkKwPVU6PjB4PD;hQi=>
INA-6	MX3GeY5kfGmxbjDBd5NigQ>?	MnnvOUDPxE1?	NXfwfVR7PiCq		M3zrfWlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiYX7kJGVTUyCyYYToe4F6	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVyNUG1PEc,OjB3MEWxOVg9N2F-
LB	MUnGeY5kfGmxbjDBd5NigQ>?	M4[yd\|Uh\|ryP	MXq2JIg>		NX;pemFNUW6qaXLpeIlwdiCxZjDQTVRMN0GtdDDhcoQhTVKNIIDheIh4[Xl?	NXTZb\|BZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NFUyPThpPkKwOVA2OTV6PD;hQi=>
B-cells	NUnF[oZVTnWwY4Tpc44h[XO\|YYm=				MUjJcohq[mm2aX;uJI9nKFCLM1vk[Yx1[SCrbjDCMYNmdGy\|IHL5JJBzd2yrZnXyZZRqd25iYYPzZZktKEmFNUCgQUAxNjByNkGg{txONg>?	NHfJcVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmyOFY5QCd-MkK5NlQ3QDh:L3G+
MOLM14	NV\WfHZOSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX3MWHQ2OyCmYYnz		NFXuRllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFMvPiEQvF2u	NXL3ZnR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOjdpPkK3O\|c1OTJ5PD;hQi=>
MV4-11	Mny4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYDORZdzOyCmYYnz		NEnlNZpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFYvOyEQvF2u	NE\MelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O\|QyOjd:L3G+
Jurkat	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEPy[Xg{KGSjeYO=		NXnRN3hYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA4NjlizszNMi=>	M2W0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
Loucy	NILXbINCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkDmN{Bl[Xm\|		NFjRNWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzveYN6KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gPE41KM7:TT6=	M3O5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
MOLT4	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH;pSWE{KGSjeYO=		MnSyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zUOEBk\WyuczDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEGwMlYh\|ryPLh?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
insect cells	MWnGeY5kfGmxbjDhd5NigQ>?				MnrOTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDIbZMufGGpZ3XkJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE4xQDlizszNMi=>	NEf4d5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
SUDHL6	NGD6SZpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIjVTo84OiCqcoO=		Mm\2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVVTIUFYh[2WubIOgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMD6xNVc3KM7:TT6=	MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
insect cells	M3rxZmZ2dmO2aX;uJIF{e2G7				NH;yR2VKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGhqey22YXfn[YQhWEl\|S3LleIEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{whUUN3MDC9JFAvPTZ3IN88UU4>	NEnhTnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
SU-DHL4	NIPZd3RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3rvUFczKGi{cx?=		MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOXLVTIUFQh[2WubIOgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxKD1iMT62JO69VS5?	NGjvOG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
Pfeiffer	M2[xOWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYiycnI5PzJiaILz		NHv1SnVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDm[Yln\mW{IHPlcIx{KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFYvQCEQvF2u	MoT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
KARPAS422	M4PtbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHKxfJo4OiCqcoO=		MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV\|QzOiClZXzsd{Bu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO\|YYmsJGlEPTBiPTC4MlEh\|ryPLh?=	NEDIS3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+
Sf21	MkWySpVv[3Srb36gZZN{[Xl?		MUOzNEBucW6\|		MnPRTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd\|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKFCLM1ugdFEyOGKndHGveY51[WepZXSgdoVkd22kaX7hcpQh\nWubDDs[Y5ofGhiaIXtZY4heDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIGDJVFIwSVSSIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6\|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSB\|Lkeg{txONg>?	NHm0S4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEGwOlk6OSd-MkixNFY6QTF:L3G+
Sf21	Mmf6SpVv[3Srb36gZZN{[Xl?		NG\o[3g{OCCvaX7z		NH3GWWhKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhemWlb33ibY5idnRiZoXscE1t\W6pdHigbJVu[W5iUFmzT{BxOTFyYnX0ZU92dnSjZ3fl[EBz\WOxbXLpcoFvfCCodXzsJIxmdme2aDDoeY1idiCyOEXhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z{MTDpcpNm[3RiY3XscJMhfXOrbnegVGlROi:DVGCgZZMhe3Wkc4TyZZRmKGGodHXyJFMxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IEOuO{DPxE1w	NUfHSW5uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixNFY6QTFpPkK4NVA3QTlzPD;hQi=>
RPMI8266	NHXD[ZVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3v3elczKGi{cx?=		M4n6b2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmDNTVgzPjZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODB3NEmg{txONg>?	MoS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MkW2NFEoRjJ6M{K1OlAyRC:jPh?=
Raji	NEf3[oZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVy3NkBpenN?		Mn;RRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUYXrpJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCwPVk2KM7:TT6=	M3PXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{K1OlAyLz5{OEOyOVYxOTxxYU6=
KARPAS422	NF;pcnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M1nKNmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtCWlCDU{SyNkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC54ODFOwG0v	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUiwOUc,Ojh6M{W4NFU9N2F-
Pfeiffer	NHvCeodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NWiyNpIyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWG[naX\m[ZIh[2WubIOgZpkhS0ONODDhd5NigSxiR1m1NEA:KDBwN{Sg{txONg>?	NEf1SGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVgxPSd-Mki4N\|U5ODV:L3G+
Saos-2	NIX2SJpyUFSVIHHzd4F6				M3nUNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NGTiSmZyUFSVIHHzd4F6				MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NIfwb2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	M{fVTZFJXFNiYYPzZZk>				NUH2[IVJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NVLN[lNUeUiWUzDhd5NigQ>?				MlHUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	M2\QU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MUfxTHRUKGG\|c3H5				M{nId5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NV3JNJo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MkXBdWhVWyCjc4PhfS=>				MorOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	NGfqNpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NWHvO3N{eUiWUzDhd5NigQ>?				NXrIVnlleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	M1nBcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M4naRZFJXFNiYYPzZZk>				Mk\udWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M4TkSZFJXFNiYYPzZZk>				Mo[zdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SUDHL6	MljuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXjlTWR6PzJiaILz		NX63WJhISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWWRJVDZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUAxNjZ3IN88UU4>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmzOkc,Ojl3M{S5N\|Y9N2F-
RPMI8226	M2jifmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWi3NkBpenN?		NWLzfoZQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ{NjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPS52OTFOwG0v	NG\XepA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFk{Pid-Mkm1N\|Q6OzZ:L3G+
Raji	MlHHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{DwSVczKGi{cx?=		Mlq0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUYXrpJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB7Lkm1JO69VS5?	NHSzXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFk{Pid-Mkm1N\|Q6OzZ:L3G+
SU-DHL6	NGe5THpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M3e0c2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNWNUSKTE[gZ4VtdHNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODR{IN88UU4>	NYTJZWMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2NFE6QTFpPkK5OlAyQTlzPD;hQi=>
MOLM13	M4rMWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX;sOYxvPzJiaILz		NGHQT29Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOV0yPMUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO\|YYmsJGdKPTBiPTCxMlch\|ryPLh?=	NGDqOm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC1N\|czOSd-M{CwOVM4OjF:L3G+
MOLM14	M{[4b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX63NkBpenN?		NXT6VmVjT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OTUG0JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGG\|c3H5MEBIUTVyIE2gOk41KM7:TT6=	MoDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUO3NlEoRjNyMEWzO\|IyRC:jPh?=
MOLM14	MYjBcpRqfHWvb4KgZZN{[Xl?	MVuxNFAhdWdxa3e=	M{HWO\|E1KGSjeYO=		MonoRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE1KGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71M452KG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:\|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegdoVt[XSrdnWgeI8h[2:wdILvcC=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	NUGyOHJQSW62aYT1cY9zKGG\|c3H5	NVvQUGpqOTByIH3nM4to	NUPyT5l3OTRiZHH5dy=>		NVX3SWxpSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUW9NVTF2IHPlcIx{KHinbn;ndoFnfGWmIHnuJI52N263IH3veZNmKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBieG:ydH;zbZMh[XRiMUCwJI1oN2upLDDwc{Bi\G2rbnnzeIVz\WRiZHHpcJkhfmmjIHfheoFo\SCmb4Pl[EBnd3JiMUSg[IF6eyCjbnSgcYVie3W{ZXSg[IFqdHliZIXybY5oKGOxbYDveY5lKGSxc3nu[{BjgSCWVV7FUEBj[XOnZDDhd5NigQ>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	M3LMVWFvfGm2dX3vdkBie3OjeR?=	M1vHfFExOCCvZz;r[y=>	NU\LS3JZOTRiZHH5dy=>		Mn73RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE1KGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71M452KG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JicILvcIln\XKjdHnvckAyODBibXevb4ctKHCxIHHkcYlvcXO2ZYLl[EBl[WmueTD2bYEh\2G4YXflJIRwe2WmIH\vdkAyPCCmYYnzJIFv\CCvZXHzeZJm\CCmYXnsfUBlfXKrbnegZ49ueG:3bnSg[I9{cW6pIHL5JGtqNTZ5IHzhZoVtdGmwZzDiZZNm\CCrbX31co9p	M1zWVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEWzO\|IyLz5\|MEC1N\|czOTxxYU6=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	Akt(T308) / PDK1(S241) / GSK-3β(S9) p-FoxO3a / FoxO3a Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax Cleaved caspase 3 / Cleaved caspase 9 p-AKT / AKT p-p65 Bim / Bcl-xl / Bid / Mcl-1 PUMA / p53	27342398 30224718 28008149
Growth inhibition assay	Cell viability Cell viability	30224718 28008149

激酶实验：^[2]	PI3K实验: 用全CLL和正常B细胞溶解物进行PI3K实验。进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer（包含 ATP)的混合物中，在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合，反应终止，在室温下温育1小时。混合物转移到PI3K ELISA板上，再温育1小时。冲洗反应板，然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液，反应5分钟，加入H₂SO₄ 终止反应。在450纳米处读数。
细胞实验：^[2]	Cell lines: CLL B 细胞或健康志愿者的T细胞或NK细胞 Concentrations: 0.01-100 μM Incubation Time: 48小时 Method: 进行MTT实验测定细胞毒性。1×10⁵个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时，然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力，分析数据。每个样本至少计数10⁴个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。基质共培养在75cm²培养瓶 (80%-100% 融合率) 培养24 小时，然后加入CLL细胞。

参考文献	[1] Lannutti BJ, et al. Blood, 2011, 117(2), 591-594. [2] Herman SE, et al. Blood, 2010, 116(12), 2078-2088. [3] Meadows SA, et al. Blood, 2011 Dec 30.

溶解度（25°C）

体外


体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+20%PEG 300+ddH2O 点击购买： PEG300	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量	415.42
化学式	C₂₂H₁₈FN₇O
CAS号	870281-82-6
储存条件	3年	-20°C	粉状
储存条件	2年	-80°C	溶于溶剂

Download Idelalisib SDF

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

临床试验信息

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03582098	Completed	Drug: Idelalisib\|Drug: Rituximab	Chronic Lymphocytic Leukaemia	Gilead Sciences	September 12 2018	--
NCT03151057	Active not recruiting	Drug: Idelalisib 100 MG\|Drug: Placebo Oral Tablet	B Cells-Tumors\|B Cell Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Gilead Sciences	July 31 2018	Phase 1
NCT03568929	Completed	Drug: Idelalisib	Follicular Non-Hodgkin''s Lymphoma Refractory	Gilead Sciences	May 25 2018	--

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

常见问题及建议解决方法

问题 1:
What is the recommended dose of CAL-101 and the route of administration for mouse studies?

回答：
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):